IngredientsAniracetam is a fully synthetic compound belonging to the racetam family of nootropic drugs. It is chemically classified as 1-(4-methoxybenzoyl)pyrrolidin-2-one, with the molecular formula CāāHāāNOā. It is also known by its original developmental code name Ro 13-5057, assigned by its originating pharmaceutical company, and is sometimes referred to by the systematic name 1-p-anisoyl-2-pyrrolidinone. Aniracetam is structurally a cyclized derivative of Ī³-aminobutyric acid (GABA).
Aniracetam has no botanical or natural source; it is entirely synthesized in the laboratory. Synthesis can be accomplished by reacting 2-pyrrolidone with anisoyl chloride in the presence of triethylamine, or alternatively, gamma-aminobutyric acid can react with anisoyl chloride, with ring closure accomplished in the presence of thionyl chloride.
Aniracetam is a white or colorless solid that forms crystals when dissolved in ethanol and has a melting point of 121ā122Ā°C. Because of the anisoyl (4-methoxybenzoyl) substituent on its pyrrolidinone ring, the molecule is fat-soluble (lipophilic), which distinguishes it from the more water-soluble prototype racetam, piracetam.
Aniracetam is available in several pharmaceutical dosage forms. It is available by prescription in Greece (under the brand names Memodrin and Referan) and Italy (brand name Ampamet), where it is indicated for mental function disorders. The compound has also been marketed in Japan under the brand name Draganon, though this brand was subsequently withdrawn from the Japanese market because of an unexpected failure in a placebo-controlled double-blind study.
Outside approved pharmaceutical markets, aniracetam is widely sold as an unregulated dietary supplement, primarily in capsule and bulk powder form. Aniracetam is a schedule 4 substance in Australia under the Poisons Standard (February 2020). Aniracetam is not approved in the United States in any dosage, though certain dosages have been studied in both animals and humans.
Aniracetam has no traditional use in any pre-modern healing system. It is entirely a product of twentieth-century pharmaceutical research. The drug was first made in the 1970s by Hoffmann-La Roche. It was designed as a structural analogue of piracetam, the first recognized nootropic compound, and developed specifically as a potential cognitive enhancer and neuroprotective agent.
Aniracetam has been clinically used in patients with mild to moderate senile dementia of the Alzheimer type. In Japan, the drug was prescribed for eight years to treat emotional disturbancesāsuch as depressed mood and anxiety/agitation, but not memory impairmentāfollowing cerebral infarction. Its regulatory trajectory has been uneven: approved as a prescription medication in parts of Europe, marketed then withdrawn in Japan, and never formally approved in the United States or by international bodies such as the European Medicines Agency (EMA) or the World Health Organization.
Unlike botanical supplements, which contain multiple phytochemical constituents, aniracetam as manufactured is a single defined chemical entity. Its pharmacological interest, however, extends to its metabolic breakdown products, which may themselves be pharmacologically active.
The parent moleculeā1-(4-methoxybenzoyl)pyrrolidin-2-oneāis the primary active species after oral administration, though its plasma half-life is extremely short. It is the compound that directly engages glutamate receptors and other central nervous system targets.
The main metabolites of aniracetam are N-anisoyl-Ī³-aminobutyric acid (N-anisoyl-GABA), 2-pyrrolidinone, and anisic acid. After oral and intravenous administration of [Ā¹ā“C]-labelled aniracetam, approximately 84% of the dose was recovered in the urine, 0.8% in the faeces, and 11% as carbon dioxide in expired air within 48 hours. Metabolites of aniracetam have been found to exhibit positive effects on memory and probably contribute to the cognition enhancement observed after aniracetam treatment. The metabolite N-anisoyl-GABA is of particular interest because it reaches substantially higher plasma concentrations than the parent drug. Plasma concentrations are generally in the 5ā15 Āµg/L range for aniracetam and 5ā15 mg/L range for N-anisoyl-GABA, a pharmacologically active metabolite, during the first few hours after oral administration of the drug.
Aniracetam is very rapidly and completely absorbed from the gastrointestinal tract; however, absolute systemic bioavailability is only about 0.2%. This profound discrepancy between complete gut absorption and extremely low systemic availability is attributable to extensive first-pass metabolism in the liver and, notably, in the lung. Total body clearance from blood (10 L/min) exceeds cardiac output, implying that the lung is a major clearance organ, and the plasma elimination half-life is very short (approximately 0.5 hours).
A pharmacokinetic bioequivalence study conducted in healthy Chinese male volunteers confirmed these parameters precisely. Twenty male volunteers were enrolled in an open, randomized, single-blind, two-sequence, two-period crossover study in which each subject, under fasting conditions, received a single oral dose of 400 mg aniracetam. Plasma concentrations were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The maximum plasma concentrations (Cmax) were 8.75 Ā± 7.82 ng/mL and 8.65 Ā± 8.70 ng/mL, Tmax were 0.4 Ā± 0.1 h, and plasma elimination half-lives (tĀ½) were 0.47 Ā± 0.16 h and 0.49 Ā± 0.24 h, respectively.
The drug is totally metabolized, as the unchanged form is not recovered in excreted fluids. The parent compound is rapidly eliminated from the body, with a short half-life and large systemic clearance. Aniracetam is largely metabolized to 4-p-anisamidobutyric acid (N-anisoyl-GABA), p-anisic acid, and 2-pyrrolidinone.
Despite its very short plasma half-life for the parent compound, therapeutic effects, such as cognitive enhancement, often last 4ā6 hours, attributed to active metabolites. The fat-soluble nature of aniracetam means that co-administration with dietary fat enhances absorption of the parent compound prior to first-pass metabolism, a consideration noted in pharmacokinetic analyses.
The best-characterized mechanism of action of aniracetam is its function as a positive allosteric modulator (PAM) of AMPA-type glutamate receptors ā the ionotropic receptors mediating fast excitatory synaptic neurotransmission in the brain. It functions primarily as a positive allosteric modulator of AMPA receptors in the brain, enhancing glutamatergic neurotransmission and thereby improving synaptic plasticity, learning, and memory processes.
At the molecular level, the mechanism of action of aniracetam on AMPA receptors was examined in outside-out patches and at glutamatergic synapses in neurons of the chick cochlear nucleus. A combination of rapid-flow analysis, using glutamate as an agonist, and kinetic modeling indicated that aniracetam slows both the rate of channel closing and the microscopic rates of desensitization, even for partially liganded receptors. Little effect was observed on the rate of recovery from desensitization or on the response to the weakly desensitizing agonist kainate.
In studies using recombinant receptors and rapid perfusion patch-clamp electrophysiology experiments, positive allosteric modulators such as aniracetam slow deactivation of AMPA receptors, or the rate at which the ion channel closes after the removal of glutamate. Aniracetam, along with related compounds, also slows desensitization, a process by which the receptor ion channel closes although glutamate remains tightly bound. The net result of slowing both deactivation and desensitization is that AMPA receptor-mediated excitatory currents are prolonged, enhancing synaptic efficacy.
Aniracetam's effects on receptor deactivation saturated at lower concentrations than its effects on desensitization, suggesting that cooperativity between homologous binding sites was required to regulate desensitization. In the presence of aniracetam, evoked excitatory synaptic currents (EPSCs) and miniature EPSCs in low quantal-content conditions had decay times similar to the time course of receptor deactivation.
In addition to ionotropic AMPA receptors, aniracetam interacts with metabotropic glutamate receptors. It appears to positively modulate metabotropic glutamate receptors (mGluRs) and AMPA-sensitive glutamate receptors, and may facilitate cholinergic transmissionāeffects which are possibly related to its mechanism of action. The neurochemistry of aniracetam is not well understood, and it is not known which specific mGluRs aniracetam modulates. Multiple studies indicate that aniracetam likely increases Ī±-secretase activity by increasing BDNF expression and positively modulating mGluRs.
The mechanism of action of the nootropics, including aniracetam, has remained elusive, although it has been speculated that indirect facilitation of cholinergic neurotransmission, especially under conditions of dysfunction, may contribute. Aniracetam has been reported to preferentially activate the reticulothalamic cholinergic pathway by enhancing acetylcholine release through group II metabotropic glutamate receptors and by increasing choline acetyltransferase activity.
Research findings indicate that aniracetam elicits a site-specific activation in mesocorticolimbic dopaminergic and serotonergic pathways in stroke-prone spontaneously hypertensive rats (SHRSP), possibly via nicotinic acetylcholine receptors in the ventral tegmental area and raphe nuclei. Results from animal studies indicate that aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems, suggesting the potential usefulness of aniracetam against various types of anxiety-related disorders and social failure/impairments.
Specifically, in animal models of anxiety, aniracetam (10ā100 mg/kg) increased total social interaction scores in a social interaction test, and the anxiolytic effects were completely blocked by haloperidol and nearly completely by mecamylamine or ketanserin, suggesting an involvement of nicotinic acetylcholine, 5-HT2A, and dopamine D2 receptors in the anxiolytic mechanism.
The area with the most developed clinical evidence for aniracetam is cognition in elderly patients with mild to moderate dementia.
Pivotal placebo-controlled trial (1991): One hundred and nine elderly patients suffering from mild to moderate cognitive impairment fulfilling NINCDS-ADRDA criteria for probable dementia of the Alzheimer type were treated for 6 months with aniracetam in a double-blind randomized study versus placebo. Patients underwent clinical, behavioural and psychometric evaluation every other month. The aniracetam group differed significantly from the placebo group by the end of the study and also showed a statistically significant improvement versus baseline in the psychobehavioural parameters, while in the placebo group a steady deterioration was observed. Tolerability to aniracetam was rated excellent. Aniracetam 1500 mg/day was more effective than placebo at 4 and 6 months in this study of 109 patients fulfilling the NINCDS/ADRDA clinical criteria guidelines for probable SDAT of mild to moderate severity.
Open-label comparative study (2012): In a prospective, open-label study, 276 patients (mean age 71 Ā± 8 years, 95 males) with cognitive disorders were enrolled, comprising four groups: a no treatment group (n = 75), an aniracetam monotherapy group, a cholinesterase inhibitor (ChEI) monotherapy group, and a combined treatment group. In this 2012 published study, aniracetam was associated with improved ratings on the Geriatric Depression Scale (GDS), used to assess emotional state. As an open-label, non-randomized study, this research carries significant methodological limitations, as it cannot rule out placebo effects or observer bias.
Overall evidence quality for Alzheimer's dementia: Results from trials in elderly patients with mild to moderate cognitive impairment due to senile dementia of the Alzheimer type suggest that aniracetam may be of benefit, with further trials required to confirm its efficacy profile and to define more precisely those patients most likely to respond to treatment. The total number of well-controlled, adequately powered randomized controlled trials remains small, and no recent large-scale confirmatory trials have been published.
Aniracetam has been used to treat dementia following stroke and in Alzheimer's disease. In Japan, the drug was prescribed for eight years to treat emotional disturbances, such as depressed mood and anxiety/agitation, but not memory impairment, following cerebral infarction. In Japan, aniracetam 200 mg three times daily is recommended in patients with anxiety and/or depression after cerebral infarction.
The physiological roles of aniracetam-sensitive brain regions may closely link with clinical efficacy towards emotional disturbances appearing after cerebral infarction, given that cerebral infarction induces various neuropsychiatric complications, including cognition deficit, emotional disturbances, sleep disorders, and behavioural abnormalities, with post-stroke depression and post-stroke anxiety being the most common neuropsychiatric disorders.
More recently, clinical research has examined aniracetam in combination with other treatments for post-stroke cognitive impairment. A study published in 2026 evaluated the clinical efficacy of Huoxue Tongqiao Decoction (HXTQD) combined with aniracetam in the treatment of post-ischemic stroke cognitive impairment (PISCI) in elderly patients. This retrospective study enrolled a total of 80 elderly patients with PSCI randomly assigned to either a control group (aniracetam alone) or an observation group (HXTQD combined with aniracetam). This study is methodologically limited by its retrospective, single-centre design.
Evidence quality: The clinical evidence for post-stroke emotional disturbance is based primarily on prescribing experience in Japan and a modest number of controlled trials. The unexpected failure of the drug in a later placebo-controlled double-blind study in Japanāwhich led to market withdrawalāunderscores the uncertainty in this area.
There is meaningful preclinical evidence supporting anxiolytic activity, derived from rodent models. Results from mouse studies indicate that aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems. Three different mouse models of anxiety (social interaction, elevated plus maze, and open-field tests) were used to establish this preclinical evidence base.
These are models of clinical disorders or symptoms that may include personality disorders, anxiety, depression, posttraumatic stress disorder, attention-deficit/hyperactivity disorder, autism, negative symptoms of schizophrenia, and sleep disorders. At present, there is no convincing evidence that promising effects of aniracetam in the animal models will guarantee its clinical efficacy.
Evidence quality: The anxiolytic evidence is currently preclinical only (animal studies). No peer-reviewed, placebo-controlled human clinical trials specifically examining aniracetam's anxiolytic effects in healthy or anxious human populations have been published as of the available literature.
Animal studies have examined aniracetam in models of depressive behavior, such as the forced swim test. Anti-depressive action on forced swim-induced immobility as a behavioral despair model has been demonstrated in rats. Aniracetam has been explored for its efficacy in treating post-stroke depression, and in a 2012 published study including 276 patients with dementia, aniracetam was associated with improved ratings in the Geriatric Depression Scale (GDS), used to assess emotional state.
Evidence quality: Evidence for antidepressant effects in humans is indirect and limited. It derives from subgroup analyses in dementia trials (not dedicated depression trials) and from animal behavioral models. Aniracetam is not currently FDA-approved or regulated, and there are no ongoing clinical trials exploring its role in any depression type or other conditions.
Some animal-model research has examined aniracetam in the context of attention and hyperactivity. Animal studies demonstrated that aniracetam has clinical potential in personality disorders, anxiety, depression, posttraumatic stress disorder, attention-deficit/hyperactivity disorder, autism, negative symptoms of schizophrenia, and sleep disorders. Aniracetam's mechanism distinguishes it from conventional ADHD pharmacotherapies such as atomoxetine (a selective norepinephrine transporter inhibitor) and methylphenidate (a non-selective dopamine and norepinephrine transporter inhibitor), underscoring its distinctive mode of action.
Evidence quality: The FDA has not approved aniracetam for ADHD treatment, due to the lack of available clinical studies that prove it is an effective treatment for such conditions. Evidence remains at the preclinical (animal) level.
Whether aniracetam meaningfully enhances cognition in neurologically healthy individuals is an important and separate question from its effects in cognitively impaired populations. A comprehensive review of preclinical pharmacological data on aniracetam provided convincing evidence of ameliorative effects on learning and memory; such effects were most clearly observed in animals exhibiting impaired cognitive abilities. In one study, no significant differences were detected between naive, placebo, and experimental groups across measures of locomotion, anxiety, and repetitive behavior, suggesting that aniracetam does not alter behavior in normal healthy mice. This study was noted as timely in light of the growing community of healthy humans self-administering nootropic drugs.
Evidence quality: There is a notable absence of rigorous, placebo-controlled human clinical trials examining aniracetam as a cognitive enhancer in healthy participants. The preclinical data most consistently demonstrate benefit in the setting of impaired cognitive function, not normal baseline cognition.
Aniracetam may prevent the production and accumulation of amyloid-Ī² (AĪ²) by increasing Ī±-secretase activity through two distinct pathways: increasing brain-derived neurotrophic factor (BDNF) expression and positively modulating metabotropic glutamate receptors. However, no research has been found in human or animal studies directly investigating the impact of aniracetam on AĪ² accumulation or production. This area therefore remains theoretical and mechanistically inferred rather than empirically demonstrated.
Clinical trials and pharmacokinetic studies have used specific doses; the following are drawn from the published scientific literature only.
Because aniracetam is fat-soluble, its absorption is influenced by co-ingestion with food containing dietary fat. Clinical trials in dementia used divided daily doses rather than single-dose regimens, consistent with the compound's short plasma half-life.
Aniracetam is well-tolerated in most clinical trials and does not increase liver enzymes; however, it is not without side effects, and healthcare practitioners are reporting unpleasant side effects in patients taking aniracetam. In the pivotal six-month, placebo-controlled trial, tolerability to aniracetam was rated as excellent.
Aniracetam has a relatively mild side effect profile in short-term clinical trials, but its long-term safety in humans is largely unknown. Short-term side effects are genuinely mild for most people: some restlessness, occasional headaches, and minor digestive discomfort. Despite the high tolerability in clinical trials, healthcare practitioners are reporting unpleasant side effects in patients taking aniracetam.
Aniracetam is not approved by the FDA in the United States, and regulatory bodies have flagged concerns about reproductive toxicity found in animal studies. Others warn of reproductive side effects, such as fertility damage and possible fetal harm to an unborn baby. These concerns derive from non-clinical animal data and have not been systematically evaluated in human studies.
The more serious concerns are the unknowns: reproductive toxicity in animals, zero long-term human safety data, an unregulated supply chain in jurisdictions such as the United States, and potential interactions with sedating medications all represent real gaps in what can be confidently said about its safety.
Prescription versions manufactured under pharmaceutical standards in countries where aniracetam is approved are a different product, quality-wise, from capsules sold by unregulated supplement companies. In jurisdictions where it is sold as an unregulated supplement, product quality, purity, and dose accuracy are not subject to regulatory oversight, introducing variability and uncertainty beyond those documented in clinical trials.
The piracetam-like nootropics, including aniracetam, are capable of achieving reversal of amnesia induced by, for example, scopolamine, electroconvulsive shock, and hypoxia ā which implies cholinergic interaction pathways. The anxiolytic mechanism of aniracetam, which involves dopamine D2 and serotonin 5-HT2A receptor pathways, theoretically creates the basis for interactions with dopaminergic or serotonergic pharmaceuticals; however, formal drug-interaction studies in humans have not been published in the peer-reviewed literature as of the available evidence base. Potential interactions with sedating medications represent one of the identified gaps in safety knowledge.
Aniracetam possesses a well-characterized molecular pharmacology at AMPA and metabotropic glutamate receptors, supported by robust in vitro and animal data. Its preclinical evidence base covers cognition, anxiety, depression, and related CNS domains, and it has undergone clinical testing primarily in elderly patients with dementia. The strongest clinical evidenceāa randomized, double-blind, placebo-controlled six-month trial in 109 Alzheimer's disease patientsādemonstrated significant benefit, but the total volume of high-quality, large-scale randomized controlled trials is limited. The drug's unexpected failure in a later placebo-controlled study in Japan and its withdrawal from that market highlight the incompleteness of the clinical evidence base. At present, there is no convincing evidence that the promising effects of aniracetam in animal models will guarantee its clinical efficacy, although it is conceivable that future clinical trials could demonstrate beneficial effects in various disease states. For healthy adults, there is a particular absence of rigorously controlled human data on cognitive enhancement.
Health conditions that Aniracetam may help support.
Body systems that Aniracetam may help support.
Go back